The table below shows Tarsus Pharmaceuticals, Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
Line item
FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
Operating cash flow
-$12.45M
-$83.03M
-$117.49M
-$49.03M
$3.75M
-$21.14M
Capital expenditure
$9.86M
$1.57M
$1.50M
$506.00K
$586.00K
$456.00K
Investing cash flow
-$42.12M
-$199.19M
$140.60M
-$144.63M
-$586.00K
-$456.00K
Dividends paid
-
-
-
-
TARS operating cash flow (10-K history)
Tarsus Pharmaceuticals, Inc. reported operating cash flow of -$12.45M for fiscal year 2025. That is up 85.0% from -$83.03M in fiscal 2024. Over the 7 fiscal years shown, operating cash flow declined from -$3.67M (FY 2019) to -$12.45M. Figures come from the company's audited annual reports as filed with the SEC.